MARKET

VXRT

VXRT

VAXART
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.14
-0.16
-1.93%
After Hours: 8.10 -0.04 -0.49% 19:58 07/23 EDT
OPEN
8.28
PREV CLOSE
8.30
HIGH
8.31
LOW
7.88
VOLUME
4.45M
TURNOVER
--
52 WEEK HIGH
24.90
52 WEEK LOW
3.500
MARKET CAP
995.27M
P/E (TTM)
-17.6880
1D
5D
1M
3M
1Y
5Y
Moderna leads COVID-19 vaccine developers; Test makers trade higher amid pandemic concerns
gopixa/iStock via Getty Images Many of the coronavirus test makers and vaccine developers are trading higher in morning hours while the U.S. stocks have trended lower amid concerns over a
Seekingalpha · 5d ago
Don’t Count on a Covid-19 Boost for Vaxart
Investor Place · 07/14 16:40
Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral
Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.
Zacks · 07/08 14:53
Vaxart Inks Antiviral Asset Licensing Pact With Altesa Biosciences
Benzinga · 07/07 15:50
Thinking about buying stock in Opiant Pharmaceuticals, RealNetworks, Vaxart, Clover Health, or Viewray?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OPNT, RNWK, VXRT, CLOV, and VRAY.
PR Newswire - PRF · 07/07 13:31
Vaxart inks $130M Vapendavir license agreement with Altesa Biosciences
Vaxart (VXRT) has signed an exclusive worldwide licensing agreement with Altesa Biosciences to develop and commercialize patented formulation of Vapendavir in a deal worth as much as $130M.Share up more
Seekingalpha · 07/07 12:16
Vaxart Announces Exclusive Worldwide License Agreement With Altesa Biosciences For Its Vapendavir Antiviral Asset; Vaxart Eligible For Up To $130M In Milestones
Milestone payments up to $130 million and royalties for global Vapendavir sales   Vapendavir has demonstrated activity against a broad spectrum of enteroviruses SOUTH SAN FRANCISCO, Calif., July 07,
Benzinga · 07/07 12:02
Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset
Milestone payments up to $130 million and royalties for global Vapendavir sales
GlobeNewswire · 07/07 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VXRT. Analyze the recent business situations of VAXART through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VXRT stock price target is 13.40 with a high estimate of 18.00 and a low estimate of 9.00.
EPS
Institutional Holdings
Institutions: 173
Institutional Holdings: 33.21M
% Owned: 27.16%
Shares Outstanding: 122.27M
TypeInstitutionsShares
Increased
46
4.14M
New
44
1.16M
Decreased
41
3.67M
Sold Out
24
4.88M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.97%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Non-Executive Chairman/Independent Director
Wouter Latour
President/Chief Executive Officer/Chief Financial Officer/Director
Andrei Floroiu
Senior Vice President/Chief Accounting Officer
Margaret Echerd
Senior Vice President/Chief Scientific Officer
Sean Tucker
Independent Director
Todd Davis
Independent Director
Michael Finney
Independent Director
David Wheadon
Independent Director
Karen Wilson
Independent Director
Robert Yedid
Declaration Date
Dividend Per Share
Ex-Div Date
10/25/2012
Dividend USD 1.108
11/09/2012
About VXRT
Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.

Webull offers kinds of Vaxart Inc stock information, including NASDAQ:VXRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VXRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VXRT stock methods without spending real money on the virtual paper trading platform.